Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Myelodysplastic Syndrome
Related studies linked through entity extraction aliases.
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Two Step Haplo With Radiation Conditioning
- Status
- RECRUITING
- Phase
- PHASE2
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes?
- Status
- RECRUITING
- Phase
- NA
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
- Status
- COMPLETED
- Phase
- PHASE3
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE2
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2